Participating Companies

Institut de la Màcula
The In­sti­tut de la Màcu­la is an in­ter­na­tio­n­al bench­mark in the treat­ment of med­i­cal and sur­g­i­cal patholo­gies of the mac­u­la, reti­na and vit­re­ous and forms part of the Hos­pi­tal Quir&oa­cute;n Te­knon. The use of state of the art tech­niques and treat­ments in dif­fer­ent spe­cial­ties places the cen­tre at the fore­front of treat­ing and han­dling sight di­s­or­ders. [more in­for­ma­tion]
Lineage Cell Therapeutics Inc. [LCTX] $369 MM MCap
Cell ther­a­py com­pany with 3 cl­ni­cal pro­grams 1) OpRe­gen, an RPE tran­s­plant ther­a­py in Ph1/2a de­vel­op­ment for the treat­ment of dry-AMD. 2) OPC1, an oli­go­den­dro­cyte pro­gen­i­tor cell ther­a­py for acute spi­nal cord in­juries with Or­phan and RMAT desig­na­tions. 3) VAC2, an al­lo­gene­ic can­cer im­munother­a­py of anti­gen-pre­sent­ing den­drit­ic cells cur­rent­ly in a Ph 1 for NS­CLC con­duct­ed by CRUK. [more in­for­ma­tion]
University of California, Los Angeles (UCLA)
The Uni­ver­si­ty of Cal­i­for­nia, Los An­ge­les, is a public re­search uni­ver­si­ty lo­cat­ed in Los An­ge­les, Cal­i­for­nia, Unit­ed States. [more in­for­ma­tion]